Clinical Trial Update: CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy [Phase 2]

View source ↗

Summary

Phase IIa randomized, double-blind, placebo-controlled trial completed to evaluate whether the combination of metformin and clemastine can promote remyelination…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Clemastine (clemastine)
• metformin (metformin)

Snippet

Sponsor: Cambridge University Hospitals NHS Foundation Trust | Conditions: Multiple Sclerosis | Phase 2 | Status: COMPLETED